BBL
ALXN

Beck Bode LLC’s Alexion Pharmaceuticals ALXN Stock Holding History

Beck Bode LLC’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-636
Closed -$73K – 320
2020
Q3 		$73K Buy
+636
New +$68.6K 0.03% 91
2020
Q2 		– Sell
-15,715
Closed -$1.69M – 55
2020
Q1 		$1.69M Sell
15,715
-10,511
-40% -$1.03M 0.78% 33
2019
Q4 		$2.84M Buy
26,226
+710
+3% +$75.9K 1.16% 32
2019
Q3 		$2.5M Buy
25,516
+1,678
+7% +$189K 1.1% 34
2019
Q2 		$3.12M Buy
23,838
+2,318
+11% +$299K 1.39% 31
2019
Q1 		$2.91M Buy
21,520
+248
+1% +$30.8K 1.4% 28
2018
Q4 		$2.07M Buy
+21,272
New +$2.51M 1.13% 30

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.47T AUM 27.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return